Alzheimer's Disease Soluble Guanylate Cyclase (sGC) Modulator Companies

Overview

This category page covers biotechnology and pharmaceutical companies developing soluble guanylate cyclase (sGC) modulators — including sGC stimulators and sGC activators — for Alzheimer's disease and related neurodegenerative disorders. The NO-sGC-cGMP pathway represents a promising therapeutic target addressing cerebral blood flow dysfunction, oxidative stress, neuroinflammation, and protein aggregation that characterize AD pathogenesis. [@evgenov2006]

Mechanism of Action

Overview

This category page covers biotechnology and pharmaceutical companies developing soluble guanylate cyclase (sGC) modulators — including sGC stimulators and sGC activators — for Alzheimer's disease and related neurodegenerative disorders. The NO-sGC-cGMP pathway represents a promising therapeutic target addressing cerebral blood flow dysfunction, oxidative stress, neuroinflammation, and protein aggregation that characterize AD pathogenesis. [@evgenov2006]

Mechanism of Action

sGC modulators work through the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) signaling axis:

• sGC Stimulators (e.g., riociguat, vericiguat): Bind to the heme moiety of sGC, stabilizing the enzyme in its active conformation and increasing cGMP production in response to NO [@stasch2011]
• sGC Activators (e.g., cinaciguat): Directly activate sGC independent of NO, useful in conditions of heme oxidation or nitrosylation [@hobbs2020]

Therapeutic Rationale for Alzheimer's Disease

| Pathological Target | sGC Modulator Effect | Relevance to AD |
|---------------------|---------------------|-----------------|
| Cerebral hypoperfusion | Vasodilation, improved CBF | [@liu2014] |
| Oxidative stress | Antioxidant, Nrf2 activation | [@zhang2020] |
| Neuroinflammation | NF-κB inhibition, microglial modulation | [@nagai2019] |
| Amyloid pathology | Modulation of APP processing | [@sullivan2022] |
| Tau pathology | Kinase/phosphatase modulation | [@thal2018] |
| Endothelial dysfunction | Improved neurovascular unit function | [@lang2021] |

Key Companies

Bayer AG — sGC Stimulators (Riociguat)

[Bayer AG](/companies/bayer) is a German pharmaceutical company that developed riociguat (Adempas), the first FDA-approved sGC stimulator.

Approved Indication: Chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) — FDA approved 2013 [@ghofrani2013]

Alzheimer's Disease Program:

• Mechanism: sGC stimulation → increased cGMP → improved cerebral blood flow, reduced neuroinflammation
• Status: Preclinical investigation
• Rationale: Cerebral vascular dysfunction is an early and progressive feature of AD; improving cerebral perfusion may slow disease progression
• Notes: Bayer has conducted preclinical studies in AD models showing reduced amyloid burden and improved cognitive function

Merck KGaA / Merck & Co. — sGC Activators

[Merck KGaA](/companies/merck-kgaa) (known as Merck outside the US) and [Merck & Co.](/companies/merck-co) (US) have explored sGC activators for cardiovascular indications.

Cardiovascular Programs: Cinaciguat (BAY 58-2667) — sGC activator for acute heart failure

Alzheimer's Disease Potential:

• Mechanism: Direct sGC activation independent of NO
• Advantage: Works in oxidative stress conditions where NO signaling is impaired
• Status: Preclinical exploration
• Notes: May be particularly relevant in AD where NO bioavailability is reduced due to oxidative stress

Pfizer — Vericiguat Development

[Pfizer](/companies/pfizer) collaborated with Merck & Co. to develop vericiguat (Verquvo), an FDA-approved sGC stimulator for heart failure (2021) [@armstrong2020]

Heart Failure Program: Vericiguat — FDA approved 2021 for chronic heart failure

Alzheimer's Disease Potential:

• Mechanism: sGC stimulation for neuroprotection
• Status: Preclinical/early clinical planning
• Rationale: The cardiovascular safety profile is established; repurposing for CNS indications is under consideration
• Notes: Pfizer has indicated interest in exploring cardiovascular-cerebral connections in neurodegeneration

AbbVie — NO-cGMP Pathway Modulation

[AbbVie](/companies/abbvie) has interest in nitric oxide signaling modulators for neurodegenerative diseases.

Related Programs:

• Nitric oxide synthase (NOS) modulators
• cGMP-dependent protein kinase (PKG) activators

• Mechanism: Targeting multiple points in the NO-sGC-cGMP axis
• Status: Discovery
• Notes: AbbVie's neuroscience pipeline includes various approaches to address vascular and metabolic aspects of AD

Roche / Genentech — cGMP Signaling Modulation

[Roche](/companies/roche) and [Genentech](/companies/genentech) have explored cGMP-modulating strategies.

Related Programs:

• PDE inhibitors (PDE9, PDE5) — cGMP pathway
• Neurotrophic factor signaling

• Mechanism: Enhancing cGMP signaling through multiple approaches
• Status: Discovery
• Notes: Roche's expertise in CNS drug development and biomarkers positions them to pursue novel cGMP-targeted approaches

Research Landscape

Academic and Preclinical Groups

| Institution | Focus Area | Key Research |
|-------------|-----------|--------------|
| University of Edinburgh | sGC and cerebral blood flow | [@liu2014] |
| University of Tubingen | sGC in neurodegeneration | [@stasch2011] |
| Johns Hopkins | cGMP and tau pathology | [@thal2018] |
| University of Michigan | sGC and neuroinflammation | [@nagai2019] |
| King's College London | NO-sGC-cGMP in AD models | [@sullivan2022] |

Clinical Trial Landscape

As of 2026, no sGC modulators have reached late-stage clinical trials for Alzheimer's disease. Early-stage programs include:

• Phase 1/2 trials planned for sGC stimulators in AD
• Biomarker studies evaluating CSF cGMP levels
• Neuroimaging studies of cerebral blood flow

Challenges and Opportunities

Challenges:

• Blood-brain barrier penetration of sGC modulators
• Optimal dosing for CNS vs. cardiovascular effects
• Long-term safety in elderly populations
• Biomarker validation for target engagement

• Addressing vascular dysfunction — an undertreated aspect of AD
• Combination potential with anti-amyloid and anti-tau therapies
• Potential for disease modification through improved cerebral perfusion
• Established safety profiles from cardiovascular indications

Pipeline Summary

| Company | Compound | Mechanism | Stage | Indication |
|---------|----------|-----------|-------|------------|
| Bayer | Riociguat | sGC stimulator | Preclinical | AD |
| Merck KGaA | Cinaciguat | sGC activator | Preclinical | AD |
| Pfizer/Merck & Co. | Vericiguat | sGC stimulator | Preclinical | AD |
| AbbVie | Various | NOS/sGC modulators | Discovery | AD |
| Roche/Genentech | Various | cGMP modulation | Discovery | AD |

Related Pages

Mechanisms

• [sGC Stimulator Therapy](/therapeutics/sgc-stimulator-therapy)
• [Nitric Oxide Signaling in Neurodegeneration](/mechanisms/nitric-oxide-signaling-neurodegeneration)
• [cGMP Signaling in Neurodegeneration](/mechanisms/cgmp-signaling-neurodegeneration)
• [Neurovascular Unit Signaling](/mechanisms/neurovascular-unit-signaling)

Related Company Categories

• [Alzheimer's Disease PDE Inhibitor Companies](/companies/ad-pde-inhibitor-companies) — related cGMP pathway
• [Alzheimer's Disease Neurovascular Therapy Companies](/companies/ad-neurovascular-cerebral-vasculature-therapy-companies)
• [Alzheimer's Disease Nitric Oxide Modulation Companies](/companies/ad-no-modulation-companies) — if exists

Therapeutic Pages

• [sGC Stimulator Therapy](/therapeutics/sgc-stimulator-therapy)
• [Nitric Oxide Modulation Therapy](/therapeutics/nitric-oxide-modulation-therapy)
• [cGMP Pathway](/mechanisms/cgmp-signaling-neurodegeneration)

References